Back to news

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Globe Newswire•19/11/2026•07:00 ET
1

Key Highlights

  • ➤Axsome will participate in two investor conferences on December 1-2, 2026
  • ➤Piper Sandler fireside chat scheduled for December 1 at 4:00 p.m. ET
  • ➤Wolfe Research virtual conference meetings scheduled for December 2
  • ➤Axsome portfolio includes FDA-approved treatments across depression, dementia agitation, sleep disorders, and migraine

NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December: * Piper Sandler 38th Annual Healthcare Conference Fireside Chat: Tuesday, December 1, 2026, at 4:00 p.m. ET in New York, NY * Wolfe Research Virtual Small & Mid-Cap Conference Investor Meetings: Wednesday, December 2, 2026 A live webcast of the Piper Sandler presentation can be accessed on the “Events & presentations” page of the “Investors” section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the event.

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in